O
EXAS

OrbiMed’s Exact Sciences EXAS Stock Holding History

OrbiMed’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100,000
Closed -$1.42M – 137
2014
Q1 		$1.42M Buy
100,000
+13,800
+16% +$186K 0.02% 134
2013
Q4 		$1.01M Buy
+86,200
New +$989K 0.01% 115

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

OrbiMed's EXAS Position: Q1 2026 in Review

OrbiMed sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 351,716 shares — an estimated $35.7M sold.

OrbiMed first reported a position in EXAS in Q2 2013 and held it in 23 quarters. The position peaked at $65.4M in Q2 2013. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • OrbiMed reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 351,716 Exact Sciences shares in Q1 2026, an estimated $35.7M.
  • OrbiMed first reported a position in Exact Sciences in Q2 2013 and held it in 23 quarters.
  • OrbiMed's Exact Sciences position peaked at $65.4M in Q2 2013.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.